Fosun Pharma: Revenue in the first three quarters of 2026 was 30.463 billion yuan, up 3.64% year on year.

Fosun Pharma announced that in the first three quarters of 2026, it achieved operating revenue of RMB 30.463 billion, up 3.64% year on year; net profit attributable to shareholders of the listed company of RMB 3.879 billion, up 15.18% year on year; and net profit after deducting non-recurring gains and losses of RMB 2.667 billion, down 8.32% year on year. In the third quarter of 2026, it achieved operating revenue of RMB 10.021 billion, up 1.44% year on year; net profit attributable to shareholders of the listed company of RMB 1.292 billion, up 15.49% year on year; and net profit after deducting non-recurring gains and losses of RMB 946 million. In the first three quarters, total R&D investment was RMB 5.247 billion, up 31.24% year on year; revenue from innovative drugs increased 15.54% year on year, accounting for 35.43% of pharmaceutical business revenue. During the reporting period, two indications of two innovative drugs were approved for marketing, the marketing application for one innovative drug was accepted, and clinical trial applications for five innovative drugs were approved.